BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Budde K, Dürr M. Any Progress in the Treatment of Antibody-Mediated Rejection? J Am Soc Nephrol 2018;29:350-2. [PMID: 29371423 DOI: 10.1681/ASN.2017121296] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Niu Q, Mendoza Rojas A, Dieterich M, Roelen DL, Clahsen-van Groningen MC, Wang L, van Gelder T, Hesselink DA, van Besouw NM, Baan CC. Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients. Front Immunol 2020;11:1972. [PMID: 32983131 DOI: 10.3389/fimmu.2020.01972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Böhmig GA, Eskandary F, Doberer K, Halloran PF. The therapeutic challenge of late antibody-mediated kidney allograft rejection. Transpl Int 2019;32:775-88. [PMID: 30955215 DOI: 10.1111/tri.13436] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
3 Mező B, Heilos A, Böhmig GA, Eskandary F, Wahrmann M, Bond G, Kozakowski N, Halloran PF, Rusai K, Prohászka Z. Complement Markers in Blood and Urine: No Diagnostic Value in Late Silent Antibody-Mediated Rejection. Transplant Direct 2019;5:e470. [PMID: 31334344 DOI: 10.1097/TXD.0000000000000915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Kolonko A, Słabiak-Błaż N, Karkoszka H, Więcek A, Piecha G. The Preliminary Results of Bortezomib Used as A Primary Treatment for An Early Acute Antibody-Mediated Rejection after Kidney Transplantation-A Single-Center Case Series. J Clin Med 2020;9:E529. [PMID: 32075220 DOI: 10.3390/jcm9020529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Cippà PE, Liu J, Sun B, Kumar S, Naesens M, McMahon AP. A late B lymphocyte action in dysfunctional tissue repair following kidney injury and transplantation. Nat Commun 2019;10:1157. [PMID: 30858375 DOI: 10.1038/s41467-019-09092-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
6 Piñeiro GJ, Montagud-Marrahi E, Ríos J, Ventura-Aguiar P, Cucchiari D, Revuelta I, Lozano M, Cid J, Cofan F, Esforzado N, Palou E, Oppenheimer F, Campistol JM, Bayés-Genís B, Rovira J, Diekmann F. Influence of Persistent Inflammation in Follow-Up Biopsies After Antibody-Mediated Rejection in Kidney Transplantation. Front Med (Lausanne) 2021;8:761919. [PMID: 34869466 DOI: 10.3389/fmed.2021.761919] [Reference Citation Analysis]
7 Mayer KA, Budde K, Jilma B, Doberer K, Böhmig GA. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials. Expert Opin Emerg Drugs 2022;:1-17. [PMID: 35715978 DOI: 10.1080/14728214.2022.2091131] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 von Samson-Himmelstjerna FA, Esser G, Schulte K, Kolbrink B, Krautter M, Schwenger V, Weinmann-Menke J, Matschkal J, Schraml F, Pahl A, Braunisch M, Amann K, Feldkamp T, Kunzendorf U, Renders L, Heemann U; TRABIO Study Group. Study protocol: the TRAnsplant BIOpsies (TRABIO) study - a prospective, observational, multicentre cohort study to assess the treatment of kidney graft rejections. BMJ Open 2022;12:e048122. [PMID: 35450886 DOI: 10.1136/bmjopen-2020-048122] [Reference Citation Analysis]